摘要
目的 通过对T淋巴细胞亚群的检测 ,从免疫学方面探讨同种异体细胞来源的组织工程化骨植入猕猴体内修复长段骨缺损的可行性。方法 用骨髓基质干细胞 (MSCs)经诱导分化为成骨样细胞后与生物衍生骨材料复合培养 ,体外构建组织工程化骨 ,植入 15只异体猕猴体内桥接桡骨 2 .5cm节段骨缺损作为实验组 ;用单纯生物衍生骨材料桥接对侧同样大小骨缺损作为对照组 ;分别于术后 1、2、3、6、12周抽取静脉血和作双侧局部组织取材 ,样本应用流式细胞术检测T淋巴细胞亚群CD3 + /CD4+ /CD45+ 、CD3 + /CD8+ /CD45+ 和CD2 8+ 阳性率。结果 术后第 1、2、3、6、12周实验组和对照组T淋巴细胞亚群CD3 + /CD4+ /CD45+ 、CD3 + /CD8+ /CD45+ 和CD2 8+ 阳性率两者差异均无显著性 (P >0 .0 5 )。结论 生物衍生骨材料和猕猴MSCs复合构建组织工程化骨植入异体猕猴体内其术后 12周内免疫反应水平低 ,可用以修复猕猴节段骨缺损。
Objective To investigate the effects of allogeneic bone marrow stromal cells (MSCs) constructing tissue engineered bones on T lymphocyte subsets after bridging segmental bone defects in rhesus monkeys.Methods MSCs being aspirated from rhesus mokeys' tibias tuberosities were induced in vitro into osteoblasts and then were loaded on bio-derived materials made from fresh human bones which were treated physically and chemically,then the constructs were implanted in 15 allogeneic monkeys to bridge 2.5 cm segmental bone defects of left radius as experimental group.Bio-derived materials only were implanted to bridge same size defects of right radius as control group.Every 3 monkeys were sacrificed at timepoints of the 1st,2nd,3rd,6th,12th week postoperatively and both sides of the implanted samples and blood samples were examined for T lymphocyte subsets CD_3 +/CD_4 +/CD_ 45 +,CD_3 +/CD_8 +/CD_ 45 + and CD_ 28 + by flow cytometry.Results T lymphocyte subsets CD_3 +/CD_4 +/CD_ 45 +,CD_3 +/CD_8 +/CD_ 45 + and CD_ 28 + at above time points in the experiment group had no significant difference as compared to control group.Conclusion Tissue engineered bones constructed with bio-derived materials and allogeneic MSCs showed low immunogenicity within 12 weeks and could be implanted to repair bone defects in monkey.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2004年第1期12-14,共3页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金重点资助项目 (39830 1 0 0 )
"863"计划重大专项资助项目 (2 0 0 2AA2 0 50 1 1 )
